about
Respiratory syncytial virus (RSV) entry is inhibited by serine protease inhibitor AEBSF when present during an early stage of infection.Blocking of opioid receptors in experimental formaline-inactivated respiratory syncytial virus (FI-RSV) immunopathogenesis: from beneficial to harmful impacts.Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation.Neonatal Immunization: Rationale, Current State, and Future Prospects.A Respiratory Syncytial Virus vaccine based on the Small Hydrophobic protein ectodomain presented with a novel lipid-based formulation is highly immunogenic and safe in adults: a first-in-humans study.Characterization of circulating RSV strains among subjects in the OUTSMART-RSV surveillance program during the 2016-17 winter viral season in the United States
P2860
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Vaccine development for respiratory syncytial virus.
@en
Vaccine development for respiratory syncytial virus.
@nl
type
label
Vaccine development for respiratory syncytial virus.
@en
Vaccine development for respiratory syncytial virus.
@nl
prefLabel
Vaccine development for respiratory syncytial virus.
@en
Vaccine development for respiratory syncytial virus.
@nl
P2860
P1476
Vaccine development for respiratory syncytial virus.
@en
P2860
P304
P356
10.1016/J.COVIRO.2017.03.012
P577
2017-04-01T00:00:00Z